Vasogen Sees 2003 PMA For Vascular Disease Immune Modulation Therapy
This article was originally published in The Gray Sheet
Executive Summary
Vasogen plans to submit a premarket approval application in 2003 for its immune modulation therapy (IMT) for peripheral arterial disease (PAD)
You may also be interested in...
Vasogen ACCLAIM trial
Double-blind, placebo-controlled Phase III study examining impact of firm's Celacade immune modulation technology on the risk of death and cardiovascular hospitalization in patients with advanced chronic heart failure has reached full enrollment of 2,000 patients, Vasogen announces May 5. Quest Diagnostics has invested in Celacade through a joint U.S. commercialization pact (1"The Gray Sheet" Nov. 26, 2001, p. 33)...
Vasogen ACCLAIM trial
Double-blind, placebo-controlled Phase III study examining impact of firm's Celacade immune modulation technology on the risk of death and cardiovascular hospitalization in patients with advanced chronic heart failure has reached full enrollment of 2,000 patients, Vasogen announces May 5. Quest Diagnostics has invested in Celacade through a joint U.S. commercialization pact (1"The Gray Sheet" Nov. 26, 2001, p. 33)...
Financings In Brief
NitroMed stent investment: Boston Scientific extends R&D collaboration with pharmaceutical firm through 2005 to develop nitric oxide elution compounds that can be used on vascular stents to "complement" Taxus line. The agreement, which expands the firms' original 2001 deal, consists of a $3 mil. up-front payment, adding to the $4 mil. equity investment and $1.5 mil. R&D payments already made by Boston Scientific. NitroMed also will receive milestone payments for development and commercialization targets, as well as royalties if a product is brought to market. Over the past year, Boston Scientific also has invested in Rubicon Medical, 3F Therapeutics and Innovia...